Based on the above data, the potential biomarkers SRC and ESR1 derived from our bioinformatics analysis may also be potential targets for luteolin in the treatment of hepatocellular carcinoma, this not only expands our hepatocellular carcinoma of luteolin treatment but also provides insight into the pathogenesis of hepatocellular carcinoma, This is consistent with the results of many previous investigators, suggesting the efficacy of already existing therapeutic targets and that new therapeutic targets may provide new strategies for the treatment of HCC. Here, ESR1 is linked to hepatocellular carcinoma.